EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing Care for Growth and Puberty in Duchenne Muscular Dystrophy: A Survey of Clinical Practice in the OPTIMIZE DMD Consortium

Claire L Wood, Funmbi Babalola, Robert W Benjamin, Carol Lam, Laura McAdam, Stefan Nicolau iD, Anne Marie Sbrocchi, Mena Scavina, Julia C Sorbara, Alexandra Ahmet, Susan Apkon, Sonum Bharill iD und 17 weitere

Muscle & Nerve · 2026

DOI: 10.1002/mus.70288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Claire L Wood und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Endocrinology, Great North Children's Hospital, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Puberty, Growth Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aim Optimizing Management of Endocrine Complications in Duchenne Muscular Dystrophy (OPTIMIZE DMD) is an international consortium of clinicians created to advance endocrine and bone clinical care in DMD. The aim of this study was to better understand current views and practices regarding investigation and management of growth and puberty concerns in individuals with DMD, relative to the 2018 Care Considerations and to inform updated guidance around endocrine care.

Methods

A survey was created and sent to 47 OPTIMIZE DMD Consortium members and allied clinicians between September and November 2024. Areas surveyed included evaluation of growth, puberty, and arrested puberty/hypogonadism, and related management including use of vamorolone, growth hormone and testosterone.

Results

Survey responses were received from 37 clinicians (79%). Most individuals were referred to endocrinology for growth and puberty concerns, with referral patterns contingent upon the endocrinology/multidisciplinary clinic model. Management discussions for growth concerns involved continued monitoring (95% of clinicians), glucocorticoid adjustment (54%) including vamorolone (35%), and growth hormone (41%). For pubertal delay, 88% of endocrinologists offered testosterone for pubertal induction, most commonly intramuscular 4‐weekly testosterone injections. Most endocrinologists (92%) offered testosterone supplementation for arrested puberty/hypogonadism, some (24%) on a case‐by‐case basis. Delivery routes were more varied, with subcutaneous injections prescribed by 52%.

Discussion

Compared with the 2018 Care Considerations, monitoring practices for growth and puberty remain largely consistent, while variability persists in management approaches. These findings provide important insights to inform future guidance and identify priorities for further education and research in endocrine management for individuals with DMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchennePubertyGrowth DisordersHumansTestosteroneMaleSurveys and QuestionnairesHypogonadismChildPuberty, DelayedHuman Growth HormoneAdolescent

Stichwörter der Autor:innen

Duchenneendocrinegrowthhypogonadismpuberty

Substanzen

TestosteroneHuman Growth Hormone

Autor:innen und Institutionen

  • Department of Paediatric Endocrinology, Great North Children's Hospital, Newcastle upon Tyne, UK.
  • Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Department of Pediatrics, Division of Endocrinology, Western University, Children's Hospital, London Health Sciences Centre, Ontario, Canada.
  • Department of Pediatrics, Division of Endocrinology, Duke University Medical Center, Durham, North Carolina, USA.
  • Department of Pediatrics, University of Toronto, Canada; Division of Endocrinology, Hospital for Sick Children, Toronto, Canada.
  • Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Canada.

ORCID-Profile: Stefan Nicolau, Sonum Bharill, Nora E Renthal, Jaclyn G Tamaroff, David R Weber, Sze Choong Jarod Wong

Zitieren

APA

Wood, C. L., Babalola, F., Benjamin, R. W., Lam, C., McAdam, L., Nicolau, S., Sbrocchi, A. M., Scavina, M., Sorbara, J. C., Ahmet, A., Apkon, S., Bharill, S., Fiscaletti, M., Kinnett, K., McMillan, H. J., Merchant, N., Nasomyont, N., Molina, M. F. O., Renthal, N. E., …, & OPTIMIZE DMD Consortium (2026). Optimizing Care for Growth and Puberty in Duchenne Muscular Dystrophy: A Survey of Clinical Practice in the OPTIMIZE DMD Consortium. Muscle & Nerve. https://doi.org/10.1002/mus.70288

Vancouver

Wood CL, Babalola F, Benjamin RW, Lam C, McAdam L, Nicolau S, et al. Optimizing Care for Growth and Puberty in Duchenne Muscular Dystrophy: A Survey of Clinical Practice in the OPTIMIZE DMD Consortium. Muscle & Nerve. 2026. doi:10.1002/mus.70288

BibTeX
@article{Wood2026,
  author = {Wood, Claire L and Babalola, Funmbi and Benjamin, Robert W and Lam, Carol and McAdam, Laura and Nicolau, Stefan and Sbrocchi, Anne Marie and Scavina, Mena and Sorbara, Julia C and Ahmet, Alexandra and Apkon, Susan and Bharill, Sonum and Fiscaletti, Melissa and Kinnett, Kathi and McMillan, Hugh J and Merchant, Nadia and Nasomyont, Nat and Molina, Maria Fernanda Ochoa and Renthal, Nora E and Smith, Pamela and Surampudi, Prasanth N and Tamaroff, Jaclyn G and Tian, Cuixia and Ward, Leanne M and Weber, David R and Wong, Sze Choong Jarod and Crane, Janet L and Rutter, Meilan M and OPTIMIZE DMD Consortium, OPTIMIZE DMD Consortium},
  title = {Optimizing Care for Growth and Puberty in Duchenne Muscular Dystrophy: A Survey of Clinical Practice in the OPTIMIZE DMD Consortium},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70288}
}
Kostenlos starten →